New hope for 'Uncuttable' lung tumors: drug combo aims to enable surgery
NCT ID NCT07408635
Summary
This study is testing whether a new drug called IBI363, combined with standard chemotherapy, can shrink stage 3 non-small cell lung cancer that is currently too advanced or complex to remove with surgery. The goal is to shrink the tumors enough so that surgery becomes a safe and viable option for the patient. The trial will enroll 43 adults in China to see how well this approach works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.